You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.
Florham Park, New Jersey
52 Week High
52 Week Low
-$0.42 per share